Economic evaluation of influenza vaccine applied to health personnel attending hospitalised oncological patients;Evaluación económica de la vacuna contra la influenza aplicada al personal de salud que atiende pacientes oncológicos hospitalizados

Revista de Salud Publica

Volumn 10, Issue 5, 2008, Pages 756-766

  Chicaíza Becerra, Liliana A ^a   García Molina, Mario ^a   Ballesteros, Mónica ^b   Gamboa, Oscar ^b   Díaz, Jorge ^a   Vega, Ricardo ^c  

^a UNIVERSIDAD NACIONAL DE COLOMBIA   (Colombia)

^b Grupo de Investigación Clínica Instituto Colombiano de Cancerología   (Colombia)

^c NONE

Author keywords

Cost benefit analysis; Economic model; Human influenza vaccine; Influenza; Neoplasm; Vaccination

Indexed keywords

INFLUENZA VACCINE;

ADULT; ARTICLE; COLOMBIA; ECONOMICS; EVALUATION; HEALTH CARE PERSONNEL; HUMAN; HUMAN RELATION; INFLUENZA; MIDDLE AGED; NEOPLASM; STATISTICS; SURVIVAL RATE; VACCINATION;

ADULT; COLOMBIA; HEALTH PERSONNEL; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MIDDLE AGED; NEOPLASMS; PROFESSIONAL-PATIENT RELATIONS; SURVIVAL RATE; VACCINATION;

EID: 68849127032     PISSN: 01240064     EISSN: None     Source Type: Journal    
DOI: 10.1590/S0124-00642008000500008     Document Type: Article

References (26)

1. Cooksley CD, Avritscher EB, Bekele BN, Rolston KV, Geraci JM, Elting LS. Epidemiology and outcomes of serious influenza-related infections in the cancer population. Cancer 2005; 104(3):618-28
2. Instituto Nacional de Salud. Epidemia de influenza A/H3N2 en Colombia. Informe Quincenal Epidemiológico Nacional 1996; 1(1):2-6.
3. Instituto Nacional de Salud. Epidemia de influenza A/H3N2/Beijing/32/92 en Ambalema Tolima 1994. Informe Quincenal Epidemiológico Nacional 1996; 1(1):6-8.
4. Instituto Nacional de Salud. Vigilancia epidemiológica para influenza y otros virus respiratorios. Informe Quincenal Epidemiológico Nacional 1998; 3(1):1-6
5. Instituto Nacional de Salud. Epidemia de influenza A/H3N2 en Colombia en 1996: actualización. Informe Quincenal Epidemiológico Nacional 1996; 1(3):39-41
6. Instituto Nacional de Salud. Influenza 1997: un nuevo aislamiento en Colombia. Informe Quincenal Epidemiológico Nacional 1997; 2(12): 172-173
7. Adult preventive health care: immunization [Internet]. Disponible en: http://www.guideline.gov. Consultado Julio de 2006.
8. Preventing pneumococcal disease among infants and young children [Internet]. Disponible en: http://www.guideline.gov. Consultado Julio de 2005.
9. Preventing pneumococcal disease among infants and young children. Norteamerica: Healthcare Infection Control Practices Advisory Committee [Internet]. Disponible en: http:// www.guideline.gov. Consultado Julio de 2005.
10. Sumaya C, Williams T. Persistence of Antibody After the Administration of Influenza Vaccine to Children with Cancer. Pediatrics 1982; 69:226-229.
11. Brydak L, Calbecka M. Immunogenicity of Influenza Vaccine in Patients with Hemato Oncological Disorders. Leukemia and Lymphoma 1999; 32:369-374
12. Chisholm J, Devine T. Response to influenza immunization during treatment for cancer. Arch Dis Child 2001; 84:496-500
13. Wilde J, McMillan J, Serwint J; Butta J, O'Riordan MA; Steinhoff M. Effectiveness of Influenza Vaccine in Health Care Professionals: A Randomized Trial. JAMA 1999;281(10):908-913.
14. Pearson M, Bridges C, Harper S. Influenza Vaccination of Health-Care Personnel. Recommendations of the Healthcare Infection Control Practices Advisory Committee (HICPAC) and the Advisory Committee on Immunization Practices (ACIP) [Internet]. Disponible en: www.cdc.gov/mmwr/preview/mmwrhtml/rr55e209a1.htm. Consultado Febrero 2006
15. Carman A, Elder L, Wallace K, McAulay A, Walker G, Murray D, et. al. Effects of influenza vaccination of health-care workers on mortality of elderly people in long-term care: a randomised controlled trial. The Lancet 2000;355(9198):93-97.
16. Potter J, Stott DJ, Roberts MA, Elder AG, O'Donnell B, Knight PV, et. al. Influenza vaccination of health care workers in long-term-care hospitals reduces the mortality of elderly patients. The Journal of Infectious Diseases 1997; 175(1):1-6.
17. Mesa S, Pérez A, Hurtado G, Arbeláez M. Effectiveness of an influenza vaccine in a working population in Colombia. Rev Panam Salud Publica 2001;10(4):232-239.
18. Salgado CD, Giannetta ET, Hayden FG, Farr BM. Preventing Nosocomial Influenza by Improving the Vaccine Acceptance Rate of Clinicians. Infection Control and Hospital Epidemiology 2004;25:923-928.
19. Avritscher EB, Cooksley CD, Geraci JM, Bekele BN, Cantor SB; Rolston KV, et. al. Costeffectiveness of influenza vaccination in working-age cancer patients. Cancer 2007 109(11):2357-64.
20. Fact Sheet for SARS Patients and Their Close Contacts [Internet]. Disponible en: http:// www.cdc.gov/ncidod/sars/factsheetcc.htm. Consultado Mayo 2006.
21. Instituto Nacional de Cancerología. Anuario Estadístico 2004. Bogotá: Instituto Nacional de Cancerología; 2005
22. Ruiz F, Amaya L, Garavito L, Ramirez J. Precios y contratos en salud estudio indicativo de precios y análisis cualitativo de contratos. Bogotá: Ministerio de la Protección Social; 2008.
23. Kempe A, Hall CB, MacDonald NE, Foye HR, Woodin KA, Cohen HJ, et al. Influenza in children with cancer. J Pediatr 1989;115(1):33-9.
24. Lin J, Zhang J, Dong X, Fang H, Chen J, Su N, et al. Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial. Lancet 2006;368(9540):991-7.
25. Allison JE, Glezen WP, Taber LH, Paredes A, Webster RG. Reactogenicity and immunogenicity of bivalent influenza A and monovalent influenza B virus vaccines in high-risk children. Infect Dis 1977;136:S672-S676.
26. Treanor JJ, Campbell JD, Zangwill KM, Rowe T, Wolff M. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med 2006;354(13):1343-51.